• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

为核医学目的从辐照的 HfO 靶中回收 Lu。

Recovery of Lu from Irradiated HfO Targets for Nuclear Medicine Purposes.

机构信息

Radiochemistry Laboratory, Vernadsky Institute of Geochemistry and Analytical Chemistry of the Russian Academy of Sciences (GEOKHI RAS), Kosygin St., 19, 119991 Moscow, Russia.

Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Leninskie Gory, 1, Bld. 2, 119991 Moscow, Russia.

出版信息

Molecules. 2022 May 16;27(10):3179. doi: 10.3390/molecules27103179.

DOI:10.3390/molecules27103179
PMID:35630655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9147805/
Abstract

A new method of production of one of the most widely used isotopes in nuclear medicine, Lu, with high chemical purity was developed; this method includes irradiation of the HfO target with bremsstrahlung photons. The irradiated target was dissolved in HF and then diluted and placed onto a column filled with LN resin. Quantitative sorption of Lu could be observed during this process. The column later was rinsed with the mixture of 0.1 M HF and 1 M HNO and then 2 M HNO to remove impurities. Quantitative desorption of Lu was achieved by using 6 M HNO. The developed method of Lu production ensures high purification of this isotope from macroquantities of hafnium and zirconium and radioactive impurities of carrier-free yttrium. The content of Lu in Lu in photonuclear production was determined. Due to high chemical and radionuclide purity, Lu obtained by the developed method can be used in nuclear medicine.

摘要

开发了一种新的生产核医学中应用最广泛的同位素之一镥(Lu)的方法,该方法具有高化学纯度;该方法包括用韧致辐射光子照射 HfO 靶。辐照后的靶溶解在 HF 中,然后稀释并放置在装满 LN 树脂的柱子上。在此过程中可以观察到 Lu 的定量吸附。然后用 0.1 M HF 和 1 M HNO 的混合物以及 2 M HNO 冲洗柱子以去除杂质。使用 6 M HNO 实现 Lu 的定量解吸。开发的 Lu 生产方法确保了从大量的铪和锆以及无载体放射性同位素钇中高度纯化该同位素。确定了光致生产中的 Lu 含量。由于具有高的化学和放射性核纯度,用所开发的方法获得的 Lu 可用于核医学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/398a312ea5a8/molecules-27-03179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/0411694c76d4/molecules-27-03179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/bd265688ee3d/molecules-27-03179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/398a312ea5a8/molecules-27-03179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/0411694c76d4/molecules-27-03179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/bd265688ee3d/molecules-27-03179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f104/9147805/398a312ea5a8/molecules-27-03179-g003.jpg

相似文献

1
Recovery of Lu from Irradiated HfO Targets for Nuclear Medicine Purposes.为核医学目的从辐照的 HfO 靶中回收 Lu。
Molecules. 2022 May 16;27(10):3179. doi: 10.3390/molecules27103179.
2
Activation of natural Hf and Ta in relation to the production of 177Lu.天然铪(Hf)和钽(Ta)的活化与177镥(177Lu)的产生相关。
Appl Radiat Isot. 2008 Oct;66(10):1300-6. doi: 10.1016/j.apradiso.2008.02.090. Epub 2008 Mar 7.
3
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects.大体积配方制备临床级即用型 Lu-DOTA-TATE 治疗剂量:复杂的放射化学方面。
Cancer Biother Radiopharm. 2017 Sep;32(7):266-273.
4
Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.用于通过氘核诱导天然镱的核反应以无载体添加形式生产用于代谢放射治疗的高比活度177g镥的激发函数。
Appl Radiat Isot. 2011 Jan;69(1):37-45. doi: 10.1016/j.apradiso.2010.08.008. Epub 2010 Aug 13.
5
Indirect Production of No Carrier Added (NCA) (177)Lu from Irradiation of Enriched (176)Yb: Options for Ytterbium/Lutetium Separation.通过富集的(176)镱辐照间接生产无载体添加(NCA)(177)镥:镱/镥分离的选择
Curr Radiopharm. 2015;8(2):107-18. doi: 10.2174/1874471008666150312161942.
6
Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy.通过对适用于放射免疫治疗的高比活度(177g)镥进行氘核辐照实现生产的物理优化。
Nucl Med Biol. 2014 May-Jun;41(5):407-9. doi: 10.1016/j.nucmedbio.2014.02.007. Epub 2014 Mar 2.
7
Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176.通过辐照富集的镱-176生产无载体添加的镥-177。
Curr Radiopharm. 2015;8(2):95-106. doi: 10.2174/1874471008666150312160855.
8
Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.研究 177Lu 标记亚甲基二膦酸盐作为潜在的用于缓解骨痛的骨靶向放射性药物。
Nucl Med Biol. 2011 Apr;38(3):417-25. doi: 10.1016/j.nucmedbio.2010.09.013. Epub 2010 Dec 3.
9
Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.基于核衰变滞后效应的癌症治疗放射性核素的核异构体分离。
Sci Rep. 2017 Mar 13;7:44242. doi: 10.1038/srep44242.
10
Characteristics of Bremsstrahlung emissions of (177)Lu, (188)Re, and (90)Y for SPECT/CT quantification in radionuclide therapy.(177)Lu、(188)Re 和(90)Y 用于放射性核素治疗的 SPECT/CT 定量的韧致辐射发射特性。
Phys Med. 2016 May;32(5):691-700. doi: 10.1016/j.ejmp.2016.04.014. Epub 2016 May 4.

本文引用的文献

1
Theranostic approaches in nuclear medicine: current status and future prospects.核医学中的治疗诊断学方法:现状与未来展望。
Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19.
2
Targeted Radionuclide Therapy: A Historical and Personal Review.靶向放射性核素治疗:历史与个人回顾。
Semin Nucl Med. 2020 Jan;50(1):87-97. doi: 10.1053/j.semnuclmed.2019.07.006. Epub 2019 Nov 6.
3
Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.用于靶向放射性核素治疗的(177)镥的生产:可用选项。
Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17.
4
Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.用于通过氘核诱导天然镱的核反应以无载体添加形式生产用于代谢放射治疗的高比活度177g镥的激发函数。
Appl Radiat Isot. 2011 Jan;69(1):37-45. doi: 10.1016/j.apradiso.2010.08.008. Epub 2010 Aug 13.
5
The treatment of myelomatosis with lutecium 177.
Br J Radiol. 1960 Jun;33:374-8. doi: 10.1259/0007-1285-33-390-374.
6
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.[177Lu-DOTAOTyr3]奥曲肽:在患者中与[111In-DTPAo]奥曲肽的比较
Eur J Nucl Med. 2001 Sep;28(9):1319-25. doi: 10.1007/s002590100574.